Clarus Therapeutics Holdings Inc
NASDAQ:CRXT
Net Margin
Clarus Therapeutics Holdings Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | US |
| Market Cap | 1.1m USD |
| Net Margin |
-193%
|
| Country | JP |
| Market Cap | 776 550.9T JPY |
| Net Margin |
-79%
|
| Country | US |
| Market Cap | 748B USD |
| Net Margin |
17%
|
| Country | DK |
| Market Cap | 4.1T DKK |
| Net Margin |
37%
|
| Country | UK |
| Market Cap | 440.4B GBP |
| Net Margin |
-4%
|
| Country | US |
| Market Cap | 367.4B USD |
| Net Margin |
45%
|
| Country | US |
| Market Cap | 333.6B USD |
| Net Margin |
4%
|
| Country | UK |
| Market Cap | 188.8B GBP |
| Net Margin |
13%
|
| Country | CH |
| Market Cap | 187.2B CHF |
| Net Margin |
20%
|
| Country | CH |
| Market Cap | 181.6B CHF |
| Net Margin |
30%
|
| Country | US |
| Market Cap | 162.7B USD |
| Net Margin |
-1%
|
Profitability Report
View the profitability report to see the full profitability analysis for Clarus Therapeutics Holdings Inc.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Clarus Therapeutics Holdings Inc's most recent financial statements, the company has Net Margin of -193%.
You don't have any saved screeners yet
